Trial
NCT03425097
Fexofenadine Use in Gastroesophageal Reflux Symptoms
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Stanford University
Collaborators
—
Condition
Gastroesophageal Reflux
Intervention
Fexofenadine
Why stopped
The study was terminated due to insufficient evidence for Fexofenadine efficacy to treat GERD symptoms after the interim analysis.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-02-17